A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment, and two-sequence of Eltrombopag 25 mg tablets relative to Revolade 25 mg tablets in healthy Thai volunteers under fasting condition.

开始日期2026-01-29

申办/合作机构

Bio-innova Co., Ltd

NCT06630221 / Not yet recruiting临床2期IIT

A Phase II Study of Eltrombopag As a Novel Therapeutic Approach for Patients with Low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) with TET2 Mutations

The purpose of this study is to evaluate if a study drug called eltrombopag can improve the blood cell counts in patients with low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) with mutations in TET2 gene, observe changes in the TET2 gene over time, and evaluate the effectiveness of the treatment. TET2 gene is one of the most frequently mutated genes (altered parts of the DNA) in MDS and CMML.
Eltrombopag is a Food and Drug Administration (FDA) approved drug for the treatment of severe aplastic anemia and low levels of platelets in patients with persistent or chronic immune thrombocytopenia (ITP) and chronic hepatitis C. Eltrombopag is considered investigational (experimental) in this study because the FDA has not approved its use in the treatment of low-risk MDS or CMML. Eltrombopag is a drug that helps stimulate the body's process of making more platelets (small components of blood that help with clotting) by interacting with specific parts of cells. This interaction starts a series of signals that encourage the growth and development of the cells that produce platelets. It was found that this drug could stop the growth of TET2 mutated cells.

开始日期2025-01-01

申办/合作机构

The Case Comprehensive Cancer Center

NCT06531018 / Not yet recruiting临床1/2期

Efficacy of Eltrombopag & Prednisolone Versus Prednisolone Monotherapy in Newly Diagnosed Immune Thrombocytopenia- A Randomized Control Trial

This will be a double-blind, placebo-control, randomized clinical trial conducted in the Department of Hematology, DMCH for one year. This study will help to establish the role of eltrombopag as a first-line therapy in newly diagnosed ITP. Newly diagnosed ITP patients will be selected after meeting inclusion and exclusion criteria, they will be thoroughly informed about the study, used drugs, randomization, risks, benefits, and follow-up. If they agree to participate, their consent will be taken and they will be enrolled in the study. A detailed history and clinical exam will be done. Primary investigation will be - CBC PBF, RBS, ANA, TSH, Anti H. pyloriIgG, Anti-HCV, APTT, and BMS (if indicated). The main outcome variable will be platelet count and number of spontaneous bleeding. Total sample size would be 100 (50 in each group). Enrolled patients would be divided into two groups (1:1) by block randomization. One group will get Eltrombopag& Prednisolone and other group will get Eltrombopag& Placebo. Researchers or any one related to the study in DMCH, patients & their attendants, no one will know which patient will get placebo or eltrombopag. Only a respectable third party will know the information. A patient would be followed up on 1st, 2nd and 4th week of starting therapy. Patients would be evaluated in every follow up by history, physical examination and investigation. History of any spontaneous bleeding event, any discomfort or new symptoms science last follow up will be noted. General examination will be performed in every follow-up. CBC, RBS, ALT, AST, creatinine will be done in every follow-up. Data will be collected on a pre-designed case record form and will be collected through face-to-face interviews, physical examination, and laboratory reports. After data collection data will be edited, cleaned, and prepared for analysis at the end of the study. The statistical analysis will be conducted using SPSS version 25 statistical software. The results of the study will be published in national and international journals.

开始日期2025-01-01

申办/合作机构

Renata Plc

100 项与艾曲波帕乙醇胺相关的临床结果

登录后查看更多信息

100 项与艾曲波帕乙醇胺相关的转化医学

登录后查看更多信息

100 项与艾曲波帕乙醇胺相关的专利（医药）

登录后查看更多信息

1,189

项与艾曲波帕乙醇胺相关的文献（医药）

2024-12-31·PLATELETS

Feasibility and effectiveness of the prolonged use of eltrombopag in addition to immunosuppression in patients with acquired aplastic anemia: a single-center real-life experience

Article

作者: Verga, Luisa ; Brioschi, Filippo ; Bernasconi, Davide Paolo ; Borin, Lorenza ; Sacco, Filippo ; Cotilli, Giulia ; Carpenedo, Monica ; Ferrari, Beatrice ; Carrer, Andrea ; Zappaterra, Arianna ; Pezzatti, Sara ; Del Castello, Lorenzo

Acquired Aplastic Anemia (AAA) is a rare disease involving primary bone marrow failure with consequent pancytopenia. The addition of the synthetic thrombopoietin-receptor agonist eltrombopag (ELT) to standard immunosuppression for the treatment of AAA has led to improvements in hemopoietic outcomes of AAA. Most of the data on the use of ELT for AAA was based on a maximum of 6 months of therapy. However, in clinical practice, a longer use of ELT is often required. This paper presents a monocentric real-life experience with prolonged use of ELT in 10 patients with AAA, showing data on effectiveness and safety. In our cohort, a high rate of response to ELT added to standard immunosuppression in patients with varying grades of severity of AAA was reported. After a median (range) observation time of 47.5 (31-75) months, the treatment with ELT was feasible with an overall response probability of 70% and was not associated with any concerning adverse event. Two episodes of relapse were reported; no signs of evolution have been reported so far. In conclusion, ELT as a dose-response-adjusted prolonged therapy associated with standard immunosuppression in AAA patients not eligible for transplant seems to be feasible to consolidate and maintain the response.

2024-12-31·PLATELETS

Molecular insights on Eltrombopag: potential mitogen stimulants, angiogenesis, and therapeutic radioprotectant through TPO-R activation

Article

作者: Subbarayan, Rajasekaran ; Chauhan, Ankush ; Balakrishnan, Ranjith ; Shrestha, Rupendra ; Murugan Girija, Dinesh ; Sadullah Usmani, Salman ; Srinivasan, Dhasarathdev ; Srivastav, Nityanand ; Ikhlas, Shoeb

The purpose of this study is to investigate the molecular interactions and potential therapeutic uses of Eltrombopag (EPAG), a small molecule that activates the cMPL receptor. EPAG has been found to be effective in increasing platelet levels and alleviating thrombocytopenia. We utilized computational techniques to predict and confirm the complex formed by the ligand (EPAG) and the Thrombopoietin receptor (TPO-R) cMPL, elucidating the role of RAS, JAK-2, STAT-3, and other essential elements for downstream signaling. Molecular dynamics (MD) simulations were employed to evaluate the stability of the ligand across specific proteins, showing favorable characteristics. For the first time, we examined the presence of TPO-R in human umbilical cord mesenchymal stem cells (hUCMSC) and human gingival mesenchymal stem cells (hGMSC) proliferation. Furthermore, treatment with EPAG demonstrated angiogenesis and vasculature formation of endothelial lineage derived from both MSCs. It also indicated the activation of critical factors such as RUNX-1, GFI-1b, VEGF-A, MYB, GOF-1, and FLI-1. Additional experiments confirmed that EPAG could be an ideal molecule for protecting against UVB radiation damage, as gene expression (JAK-2, ERK-2, MCL-1, NFkB, and STAT-3) and protein CD90/cMPL analysis showed TPO-R activation in both hUCMSC and hGMSC. Overall, EPAG exhibits significant potential in treating radiation damage and mitigating the side effects of radiotherapy, warranting further clinical exploration.

2024-12-31·Hematology (Amsterdam, Netherlands)

Safety and efficacy of eltrombopag in patients with aplastic anemia: a systematic review and meta-analysis of randomized controlled trials

Review

作者: Liu, Cangchun ; Kang, Lei ; Liu, Cong ; Liu, Ying ; Guo, Huaipeng

OBJECTIVE:

This article conducts a systematic review of eltrombopag combined with immunosuppressive therapy for the treatment of aplastic anemia (AA), to demonstrate the effectiveness and safety of eltrombopag.

METHODS:

PubMed, Cochrane Library, Embase, OVID, Web of Science, China National Knowledge Infrastructure, and Wanfang databases were searched. Studies that met the inclusion criteria were collected, ranging from the establishment of the database to August 2023. Two reviewers performed meta-analyses using the Cochrane systematic review method and RevMan 5.3 software.

RESULTS:

This meta-analysis enrolled 5 studies with a total of 542 AA patients, including 274 in the experimental group and 268 in the control group. Meta-analyses were performed for efficacy and adverse reactions. The endpoint of effects included 6-month complete response (CR), 6-month partial response (PR), and 6-month overall response (OR). Eltrombopag combined with immunotherapy showed significant improvements in 6-month CR (OR: 2.20; 95% CI;1.54-3.12; P < 0.0001) and 6-month OR (OR = 3.66, 95% CI 2.39-5.61, P < 0.001)compared to immunosuppressive therapy for AA patients. In terms of safety, eltrombopag combined with immunosuppressive therapy showed significantly increased pigment deposition and abnormal liver function compared to immunosuppressive therapy alone.

CONCLUSION:

Compared to immunosuppressive therapy alone, eltrombopag combined with immunosuppressive therapy showed significant improvements in 6-month CR and 6-month OR. However, it also resulted in increased pigment deposition and abnormal liver function in terms of safety.

204

项与艾曲波帕乙醇胺相关的新闻（医药）

2024-12-18

·摩熵医药

CDK4/6抑制剂“三足鼎立”，齐鲁制药率先杀入首仿！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 12月18日，据CDE官网最新公示，齐鲁制药提交的4类仿制药阿贝西利片上市申请获得受理。据摩熵医药数据库显示，阿贝西利片在国内暂无仿制药企获批，而齐鲁制药则是首家提交该品种仿制申请的药企。若齐鲁制药能顺利获得批准，有望斩获国内首仿。截图来源：CDE CDK4/6抑制剂“三足鼎立”，齐鲁制药入局国内首仿作为首个纳入国家医保目录的CDK4/6抑制剂，阿贝西利自2021年起即被纳入医保体系，国内市场的销售额持续攀升。2023年阿贝西利片在全国院内市场的销售额超6亿元，同比增长达70.28%，进入2024年，其市场表现依然强劲，上半年销售额已接近4亿元。截图来源：摩熵医药（原药融云）全国医院销售数据库目前，阿贝西利是唯一同时覆盖早期和晚期乳腺癌患者治疗，并纳入国家医保范围的CDK4/6抑制剂。在全球CDK4/6抑制剂市场中，长期以来形成了“三足鼎立”的竞争态势，其中辉瑞凭借2015年推出的哌柏西利率先占据市场；而礼来的阿贝西利与诺华的瑞波西利均在2017年获得美国监管批准，三者最初均聚焦于晚期HR+/HER2-乳腺癌的治疗。然而，礼来的阿贝西利凭借其在早期乳腺癌适应症上的突破，成功重塑了市场格局。目前，阿贝西利片在国内仅原研药企获批上市，礼来已完全垄断了这一细分市场，享有100%的市场份额。截图来源：摩熵医药（原药融云）中国药品批文数据库在早期乳腺癌这一更广阔的治疗领域中，礼来目前尚未遭遇直接竞争对手，其市场地位稳固且前景广阔。然而，随着国内仿制药市场的逐步推进，齐鲁制药提交了阿贝西利片的4类仿制药申请，成为该品种首家申报的企业。若齐鲁制药能顺利获批，有望拿下国内首仿，打破原研药企一家独大的市场局面，为市场带来新的变化。截图来源：摩熵医药（原药融云）中国药品审评数据库齐鲁制药超50款品种布局，抢13款品种首仿截至目前，齐鲁制药（含子公司）已提交超过50个品种的仿制药申请。今年以来，该药企已有超过20款品种报产在审，涵盖多个治疗领域：包括6个神经系统及抗感染系统药物、4个心血管系统药物、3个抗肿瘤与免疫调节药物，以及感觉系统、呼吸系统、消化系统与代谢、血液和造血系统药物各2个，此外还有1个皮肤病药物。齐鲁制药今年报产在审的仿制药（标红品种为国内暂无仿制药获批上市）截图来源：摩熵医药（原药融云）中国药品审评数据库此外，齐鲁制药提交的阿贝西利片、苯磺酸美洛加巴林片、丙酸氟替卡松鼻喷雾剂、布瑞哌唑口崩片、布瑞哌唑片等13个品种，目前暂无国内药企获批仿制，齐鲁制药将与多家药企竞争首仿。 2024年至今，齐鲁制药（含子公司）有超40款品种过评，其中拿下利奥西呱片、二甲双胍恩格列净片(Ⅵ)、恩曲他滨利匹韦林丙酚替诺福韦片、氯苯唑酸葡胺软胶囊、盐酸苯达莫司汀注射用浓溶液、艾曲泊帕乙醇胺片、阿帕他胺片7款品种首仿。结语在医药行业的激烈竞争中，创新是推动行业发展的关键。CDK4/6抑制剂领域的竞争同样激烈，众多企业正积极探索早期乳腺癌适应症的开发，为患者带来更多希望。齐鲁制药作为首仿赛道的领跑者，将继续秉持创新精神，为患者提供更多优质、高效的药品选择，助力医药行业蓬勃发展。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“深度报告”，获取价值18600元，报告大礼包后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作 👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

上市批准医药出海申请上市

2024-12-16

·drugs

American Society of Hematology, Dec. 7 to 10

The annual meeting of the American Society of Hematology was held from Dec. 7 to 10 in San Diego and attracted participants from around the world, including hematology specialists as well as clinical practitioners and other health care professionals. The conference featured presentations focusing on the diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems. In one study, Kristin A. Shimano, M.D., of the University of California, San Francisco, Benioff Children's Hospital, and colleagues found that for pediatric patients with newly diagnosed immune thrombocytopenia (ITP) within three months of diagnosis, eltrombopag leads to a more durable platelet response during weeks six 6 to 12 of treatment compared with standard treatments. The authors evaluated the use of eltrombopag (a thrombopoietin receptor agonist approved for persistent or chronic ITP) during the new-diagnosis phase and compared the responses between patients treated with eltrombopag and standard therapies (intravenous immunoglobulin, prednisone, and anti-D globulin). The researchers found that compared with those treated with standard therapies, a greater proportion of patients treated with eltrombopag had a platelet count of more than 50,000 during weeks 6 through 12 of the study without requiring a rescue therapy. "This has a huge potential to change our approach to the management of newly diagnosed pediatric ITP," Shimano said. "For patients with moderate bleeding or significant impact on quality of life due to their ITP, eltrombopag may be a good option to get the platelets to a more hemostatic level during the time that they have active ITP." Several authors disclosed financial ties to pharmaceutical and biotechnology companies, including Novartis, which manufactures eltrombopag and funded the study. Abstract No. 709 In another study, Rushad Patell, M.D., of Harvard Medical School in Boston, and colleagues found that the use of glucagon-like peptide-1 (GLP-1) receptor agonists leads to a significant reduction in the risk for blood clots among patients with type 2 diabetes. The authors compared patients who newly started a GLP-1 receptor agonist for type 2 diabetes to patients being prescribed another antidiabetic medication to assess rates of blood clots at one year. The researchers observed a 20 percent reduction in venous thromboembolism rates at 12 months. This benefit was seen across patients with different body mass index at the time of starting the study and included a breakdown for the two different types of blood clots (pulmonary embolism and deep vein thrombosis) when evaluated individually. "This was the first time this medication has been shown to impact venous thromboembolism to our knowledge," Patell said. "If these results are confirmed, they suggest that the use of these medications can have benefits beyond what has already been shown and can now include a reduction of blood clots." Two authors disclosed financial ties to the pharmaceutical and biotechnology industries. Abstract No. 701 Jenny Paredes, Ph.D., of the City of Hope National Medical Center in Duarte, California, and colleagues found that increasing dietary fiber intake is beneficial for the intestinal microbiome of allogeneic hematopoietic cell transplantation (allo-HCT) patients and could lead to an increase in overall survival and a reduction in acute graft-versus-host disease (GVHD). The authors assessed a preclinical mouse model of GVHD with defined diet fiber concentrations and also analyzed the dietary patterns of allo-HCT patients. The investigators found that dietary fiber intake in allo-HCT patients (days −7 to −30) positively correlated with higher overall survival, lower acute GVHD cumulative incidence, and lower gastrointestinal-GVHD cumulative incidence (landmark analysis to 24 months). In addition, fiber consumption positively correlated with microbial alpha-diversity, relative abundance of butyrate producers, and production of short chain fatty acids (SCFAs). In the murine model of GVHD post allo-HCT, the researchers determined that a diet rich in fiber (12 percent cellulose) increased survival to GVHD, led to a higher relative abundance of butyrate producers, and modulated gene expression associated with higher epithelial homeostasis and lower T-cell mediated inflammation (single cell sequencing). "Although follow-up studies on the strategies that can be used to increase dietary fiber in allo-HCT patients are in course, we would like to recommend reevaluating the nutritional plans and meals for allo-HCT patients and including multiple options of high fiber foods for every meal and beverage," Paredes said. "Increasing fiber consumption by 10 to 20 grams per day, based on our results, would lead to a more diverse microbiome, an increase in SCFA production, and consequently, to better overall survival (the Recommended Dietary Allowance for dietary fiber by the U.S. Department of Agriculture is 25 to 30 grams per day)." One author disclosed financial ties to the pharmaceutical and biotechnology industries. Abstract No. 259 ASH: Blinatumomab + Chemo Aids Survival in B-Cell Acute Lymphoblastic Leukemia THURSDAY, Dec. 12, 2024 -- For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia with an average or high risk for relapse, adding blinatumomab to combination chemotherapy is associated with improved disease-free survival, according to a study published online Dec. 7 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 7 to 10 in San Diego. Read Full Text ASH: Reduced-Dose Anticoagulants Not Noninferior for Recurrent VTE FRIDAY, Dec. 6, 2024 -- Noninferiority of reduced- versus full-dose anticoagulants cannot be proven in patients with venous thromboembolism who need extended anticoagulation, according to a study to be presented at the annual meeting of the American Society of Hematology, held from Dec. 7 to 10 in San Diego. Read Full Text ASH: Auto-HCT Not Beneficial for Mantle Cell Lymphoma With Undetectable Residual Disease FRIDAY, Dec. 6, 2024 -- Autologous hematopoietic cell transplant is not beneficial for patients with mantle cell lymphoma in first complete remission with undetectable minimal residual disease, according to a study to be presented at the annual meeting of the American Society of Hematology, held from Dec. 7 to 10 in San Diego. Read Full Text ASH: Complications Common With Controlled Ovarian Hyperstimulation in Sickle Cell Anemia THURSDAY, Nov. 14, 2024 -- Many individuals with sickle cell anemia undergoing controlled ovarian hyperstimulation with oocyte cryopreservation have complications, according to a study scheduled for presentation at the annual meeting of the American Society of Hematology, to be held from Dec. 9 to 12 in San Diego. Read Full Text ASH: GLP-1 RA Use Tied to Lower Rate of Venous Thromboembolism in Diabetes THURSDAY, Nov. 14, 2024 -- For patients with type 2 diabetes mellitus, glucagon-like peptide 1 receptor agonist use is associated with a lower risk for venous thromboembolism, according to a study scheduled for presentation at the annual meeting of the American Society of Hematology, to be held from Dec. 9 to 12 in San Diego. Read Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果上市批准ASH会议

2024-12-14

·摩熵医药

2亿注射剂，科伦药业迎来第4家过评！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 12月12日，据NMPA官网公示，科伦药业提交的盐酸布比卡因注射液通过仿制药一致性评价。据摩熵医药数据库显示，科伦药业是国内第4家过评该品种的药企，此外盐酸布比卡因注射液在2023年全国院内市场的销售额超2亿元，市场前景广阔。截图来源：NMPA官网布比卡因（bupivacaine）是一种酰胺类的局部麻醉药，主要通过可逆地阻断快速电压门控钠离子通道来阻断神经脉冲的传递，从而达到镇痛效果。其盐酸盐即盐酸布比卡因早在1972年就已经在美国作为局部麻醉药上市，据摩熵医药数据库，盐酸布比卡因注射液在2023年全国院内市场的销售总额超2.4亿元。截图来源：摩熵医药（原药融云）全国医院销售数据库目前，盐酸布比卡因注射液已有山东华鲁制药、湖南科伦制药、上海禾丰制药等10家企业拥有该品种的生产批文，其中过评的有4家药企，上海禾丰制药是首家过评该品种的药企。截图来源：摩熵医药（原药融云）过评药品汇总数据库此外，今年10月，科伦药业子公司湖南科伦制药的“布比卡因脂质体注射液”获批上市，视同通过一致性评价，成为我国第二个上市产品。此次，科伦药业的盐酸布比卡因注射液迎来过评，成为业界唯一拥有两种布比卡因制剂的生产批文的药企。目前，在仿制药布局方面，盐酸布比卡因注射液在国内已有19家药企提交仿制申请，均处于审评审批阶段。截图来源：摩熵医药（原药融云）中国药品审评数据库 2024年至今，科伦药业（含子公司）有28款品种过评，其中ω-3甘油三酯(2%)中长链脂肪乳/氨基酸(16)/葡萄糖(30%)注射液、注射用美罗培南/氯化钠注射液、甘露醇注射液、ω-3甘油三酯(2%)中长链脂肪乳/氨基酸(16)/葡萄糖(16%)注射液、艾曲泊帕乙醇胺片5款品种为首家过评。结语科伦药业在仿制药领域的强劲实力再次得到验证。随着盐酸布比卡因注射液成功通过一致性评价，科伦药业已成为国内第四家获得此殊荣的企业。同时，科伦药业在布比卡因制剂领域的领先地位也进一步巩固，成为业界唯一同时掌握两种布比卡因制剂生产技术的企业。相信在未来的市场竞争中，科伦药业将继续保持其领先地位，为患者提供更多优质、高效的药品。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“深度报告”，获取价值18600元，报告大礼包后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作 👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

一致性评价上市批准

100 项与艾曲波帕乙醇胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	艾曲波帕乙醇胺	B02BX05	DB06210

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肝素诱导血小板减少	澳大利亚	Novartis Pharmaceuticals Australia Pty Ltd.	2024-09-12
再生障碍性贫血	欧盟	Novartis Europharm Ltd.	2010-03-11
再生障碍性贫血	冰岛	Novartis Europharm Ltd.	2010-03-11
再生障碍性贫血	列支敦士登	Novartis Europharm Ltd.	2010-03-11
再生障碍性贫血	挪威	Novartis Europharm Ltd.	2010-03-11
免疫性血小板减少症	欧盟	Novartis Europharm Ltd.	2010-03-11
免疫性血小板减少症	冰岛	Novartis Europharm Ltd.	2010-03-11
免疫性血小板减少症	列支敦士登	Novartis Europharm Ltd.	2010-03-11
免疫性血小板减少症	挪威	Novartis Europharm Ltd.	2010-03-11
血小板减少症	美国	Novartis Pharmaceuticals Corp.	2008-11-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
实体瘤	临床3期	中国台湾	Novartis AG	2014-03-01
慢性肝病	临床3期	美国	GSK Plc	2008-06-01
慢性肝病	临床3期	阿根廷	GSK Plc	2008-06-01
慢性肝病	临床3期	比利时	GSK Plc	2008-06-01
慢性肝病	临床3期	加拿大	GSK Plc	2008-06-01
慢性肝病	临床3期	法国	GSK Plc	2008-06-01
慢性肝病	临床3期	印度	GSK Plc	2008-06-01
慢性肝病	临床3期	意大利	GSK Plc	2008-06-01
慢性肝病	临床3期	巴基斯坦	GSK Plc	2008-06-01
慢性肝病	临床3期	波兰	GSK Plc	2008-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2024 人工标引	临床2期	免疫性血小板减少症一线	23	Low-Dose Corticosteroids (LD-CIS) + Low-Dose Eltrombopag (LD-EPAG)	淵醖構壓醖糧鹹蓋齋願(蓋願淵衊選憲膚衊襯廠) = 夢蓋鹹鏇獵願簾鹽廠淵艱選鹹齋艱窪鹽餘廠艱 (淵築網鏇膚糧蓋範齋壓 ) 更多	积极	2024-12-09
ASH2024	N/A	免疫性血小板减少症	-	Eltrombopag	鏇鹽範鹽壓醖鑰壓壓築(憲衊選壓構範製鹹繭窪) = 20 AEs grade 3 or higher (including 6 SAEs) in the epag arm, and 6 (3 SAEs) in the SOC arm during the first 12 weeks. The most common AEs were headache (3 epag, 3 SOC) and epistaxis (1 epag, 2 SOC). Drug-related SAEs occurred in 6 pts (epag - 2 elevated LFTs, 2 headache (HA); SOC - 1 allergic reaction, 1 HA). There were no thromboembolic events. There was 1 intracranial hemorrhage in the epag arm. 艱襯遞範獵餘鑰醖鹹廠 (衊淵範壓憲選鏇廠築鑰 )	-	2024-12-09
				Standard First-Line Therapy (SOC)
ASH2024	N/A	免疫性血小板减少症	-	Eltrombopag	築獵餘願憲膚艱製簾遞(鏇艱遞壓網餘淵憲夢淵) = 膚醖糧製淵壓蓋衊簾壓構鹽襯襯獵廠觸獵觸顧 (艱遞鏇鑰鹽觸製醖製廠 ) 更多	-	2024-12-08
				Romiplostim	築獵餘願憲膚艱製簾遞(鏇艱遞壓網餘淵憲夢淵) = 鑰襯構觸遞廠築顧夢廠構鹽襯襯獵廠觸獵觸顧 (艱遞鏇鑰鹽觸製醖製廠 ) 更多
RACE trial (ASH2024)	临床3期	再生障碍性贫血一线	-	Eltrombopag plus IST	夢餘膚衊鹽襯鏇夢糧願(網襯製淵餘衊憲鏇積壓) = 蓋襯鬱鏇膚顧獵獵選獵積艱鏇蓋艱鏇窪餘顧衊 (艱艱襯顧醖壓襯廠積壓 )	不佳	2024-12-08
				IST alone	夢餘膚衊鹽襯鏇夢糧願(網襯製淵餘衊憲鏇積壓) = 蓋膚鹹網構糧廠遞衊範積艱鏇蓋艱鏇窪餘顧衊 (艱艱襯顧醖壓襯廠積壓 )
ASH2024	N/A	免疫性血小板减少症	-	Eltrombopag	艱壓蓋製獵壓艱衊窪衊(願簾繭淵鏇鏇築鹹獵繭) = 觸網蓋艱襯鑰繭獵遞積齋夢醖膚範窪糧艱壓築 (襯築齋淵觸齋糧壓淵襯 ) 更多	-	2024-12-08
				Romiplostim	艱壓蓋製獵壓艱衊窪衊(願簾繭淵鏇鏇築鹹獵繭) = 範醖夢壓膚衊繭蓋蓋齋齋夢醖膚範窪糧艱壓築 (襯築齋淵觸齋糧壓淵襯 ) 更多
SOHO2024	N/A	-	-	Eltrombopag (twice-weekly dosing)	鬱蓋艱觸鏇衊製遞醖鹽(繭夢遞簾顧築齋鬱餘夢) = mild transient hepatotoxicity 艱觸醖積構夢觸構製積 (夢鹹築蓋衊淵夢醖鬱鹹 )	-	2024-09-04
NCT04917679 (Pubmed \| Blood) 人工标引	临床2期	免疫性血小板减少症	102	Eltrombopag plus diacerein	構範憲簾網製觸構齋築(網壓襯繭觸鑰艱糧選構) = 膚齋鑰衊獵鹹顧夢鬱製襯積積築壓選選廠蓋觸 (願醖選餘窪艱齋醖餘製 ) 更多	积极	2024-07-03
				Eltrombopag	構範憲簾網製觸構齋築(網壓襯繭觸鑰艱糧選構) = 獵鹹窪觸蓋構齋壓餘鑰襯積積築壓選選廠蓋觸 (願醖選餘窪艱齋醖餘製 ) 更多
NCT05466201 (EHA2024) 人工标引	临床2期	骨髓衰竭疾病	63	Eltrombopag	夢醖遞壓鹽築繭夢鹹鹹(築夢艱蓋糧鹹範壓襯夢) = 鹽衊願觸壓範壓範鬱廠選簾糧遞鏇積餘願製築 (鏇鹽窪蓋襯獵製鬱鑰積 ) 更多	积极	2024-05-14
				Eltrombopag (Supportive Care)	夢醖遞壓鹽築繭夢鹹鹹(築夢艱蓋糧鹹範壓襯夢) = 廠獵齋鬱築鏇遞範壓蓋選簾糧遞鏇積餘願製築 (鏇鹽窪蓋襯獵製鬱鑰積 ) 更多
CECGA (EHA2024)	N/A	再生障碍性贫血	62	Hetrombopag (HETROM) + Cyclosporin A (CsA)	遞築觸願願餘積觸鏇廠(壓選鹹糧廠膚鏇齋鏇壓) = 顧鏇鏇顧獵網鬱齋鑰積鏇淵鏇積願餘鏇夢鬱觸 (衊醖艱醖壓繭願鑰壓範 ) 更多	积极	2024-05-14
				Eltrombopag (EPAG) + Cyclosporin A (CsA)	鏇壓衊糧製餘選鑰範鬱(鬱糧鬱蓋淵夢壓膚衊範) = 選齋製窪襯憲鏇鏇壓遞糧鹽夢淵夢構鹹觸糧壓 (積顧鹹餘鹽觸構淵憲顧 ) 更多